NTHU
25.11.2021 11:02:06 CET | Business Wire | Press release
Japan has donated five batches of the AZ COVID-19 vaccine to Taiwan, and Taiwan has reciprocated by providing treatment at NTHU’s Boron Neutron Capture Therapy Center (BNCTC) for a 20-year-old Japanese woman suffering from a malignant brain tumor. The treatment was a success, and she has now returned to school.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005795/en/
The doctor in charge of the treatment was Yi-Wei Chen of the Oncology Department at Taipei Veterans General Hospital (TVGH). He said that only Taiwan and Japan have medical centers using boron neutron capture therapy (BNCT) to treat cancer. However, Japan’s Ministry of Health, Labor, and Welfare has not yet approved BNCT for treating malignant brain tumors, leaving Taiwan as the only source of treatment for malignant brain tumors that are difficult to treat by surgery.
Chen said that the Japanese patient was originally diagnosed with rhabdomyosarcoma of the right ear canal at the age of six. After surgery and chemotherapy, the condition was stable for a time. Unexpectedly, the tumor recurred in 2018, and the tumor metastasized to the hindbrain. After it was determined that it turned out to be malignant peripheral nerve sheath tumor, she received heavy particle and CyberKnife treatment in Japan, but the tumor still recurred.
Thus she decided to come to Taiwan for BNCT, and arrived in April 2021. By that time the tumor was 6–7 cm in size, but after the first round of irradiation at the THOR BNCT Cancer Center, it shrank by 80%, and the compression on her neck relieved considerably, much to the delight of the medical team, and she returned to Japan. However, at the end of July, some signs of recurrence were discovered, and she was advised to return to Taiwan for a second round of irradiation.
She went to the THOR BNCT Cancer Center for treatment on September 17. After the injection of the Boron-10 drug and a 20-minute session of neutron source irradiation, she had a group photo in front of the NSTDC with the medical team, who presented her with a teddy bear wearing a graduation cap, as a way of wishing her a speedy “graduation” from her cancer. Afterwards, she thanked the medical team in fluent English.
Working closely with the TVGH, the BNCTC has treated over one hundred patients from all over the world, including Spain, Brazil, Australia, Singapore, Japan, and China.
BNCT is a kind of targeted radiotherapy in which the patient is first injected with a boron-containing drug; once the drug has accumulated in the tumor, the neutron beam from the nuclear reactor is used to irradiate the tumor, and the high-energy particles generated by the boron neutron capture reaction effectively kill off the tumor cells, without damaging nearby normal cells. Thus BNCT is well suited for treating diffuse cancers and cases in which surgery is contraindicated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005795/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition16.9.2026 15:30:00 CEST | Press release
As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916593883/en/ Walid Sheta, President, MEA Zone at Schneider Electric, releasing the company's 2026 Industrial AI in CPG Study for the UAE, at Schneider Electric Innovation Summit MEA (Photo: AETOSWire) Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’ Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innova
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 14:23:00 CEST | Press release
The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, w
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release
AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release
New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr
Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release
Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
